ECSP088353A - Composiciones farmacéuticas que comprenden sustancias antidiabéticas combinadas para su uso en diabetes mellitus - Google Patents
Composiciones farmacéuticas que comprenden sustancias antidiabéticas combinadas para su uso en diabetes mellitusInfo
- Publication number
- ECSP088353A ECSP088353A EC2008008353A ECSP088353A ECSP088353A EC SP088353 A ECSP088353 A EC SP088353A EC 2008008353 A EC2008008353 A EC 2008008353A EC SP088353 A ECSP088353 A EC SP088353A EC SP088353 A ECSP088353 A EC SP088353A
- Authority
- EC
- Ecuador
- Prior art keywords
- combination
- diabetes mellitus
- thiazolidinediones
- pharmaceutical compositions
- combined anti
- Prior art date
Links
- 230000003178 anti-diabetic effect Effects 0.000 title abstract 3
- 239000003472 antidiabetic agent Substances 0.000 title abstract 3
- 239000000126 substance Substances 0.000 title abstract 3
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229940123464 Thiazolidinedione Drugs 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 150000001467 thiazolidinediones Chemical class 0.000 abstract 3
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 abstract 2
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 abstract 2
- 229940123208 Biguanide Drugs 0.000 abstract 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 abstract 2
- 229940100389 Sulfonylurea Drugs 0.000 abstract 2
- 239000003888 alpha glucosidase inhibitor Substances 0.000 abstract 2
- 150000004283 biguanides Chemical class 0.000 abstract 2
- 229950004994 meglitinide Drugs 0.000 abstract 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 abstract 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 abstract 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 abstract 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 abstract 1
- 229960002632 acarbose Drugs 0.000 abstract 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 229960004580 glibenclamide Drugs 0.000 abstract 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 abstract 1
- 229960004346 glimepiride Drugs 0.000 abstract 1
- 229960001381 glipizide Drugs 0.000 abstract 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 abstract 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 abstract 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 1
- 229960003105 metformin Drugs 0.000 abstract 1
- 229960001110 miglitol Drugs 0.000 abstract 1
- 229960000698 nateglinide Drugs 0.000 abstract 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 abstract 1
- 229960005095 pioglitazone Drugs 0.000 abstract 1
- 229960002354 repaglinide Drugs 0.000 abstract 1
- 229960004586 rosiglitazone Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229960001641 troglitazone Drugs 0.000 abstract 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 abstract 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención esta relacionada con la industria farmacéutica en general y con la industria farmacéutica preparadora de medicamentos para el control de diabetes en particular. Más específicamente se trata de una composición formada por sustancias antidiabéticas de diferentes tipos en combinación. La composición se caracteriza en que dicha combinación o asociación consiste en dos o tres sustancias antidiabéticas seleccionadas del conjunto formado por: sulfonilureas, meglitinidas, biguanidas ó inhibidores de alfa-glucosidasa con tiazolidinedionas para el tratamiento de la diabetes mellitus tipo 2 en nuevas formulaciones y porque las sulfonilureas son seleccionadas del conjunto formado por glipizida, gliburida, glimepirida; meglitinidas, repaglinida, nateglinida, tiazolidinedionas o una combinación de estas; biguanidas como metformina; inhibidores de la alfa-glucosidasa conocidos como acarbosa, miglitol en asociación o combinación con tiazolidinedionas conocidas como pioglitazona, rosiglitazona, troglitazona, como base o una sal fisiológicamente aceptada.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MXPA05010977A MXPA05010977A (es) | 2005-10-12 | 2005-10-12 | Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP088353A true ECSP088353A (es) | 2008-05-30 |
Family
ID=37943034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2008008353A ECSP088353A (es) | 2005-10-12 | 2008-04-07 | Composiciones farmacéuticas que comprenden sustancias antidiabéticas combinadas para su uso en diabetes mellitus |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1935424A1 (es) |
| BR (1) | BRPI0617409A2 (es) |
| EC (1) | ECSP088353A (es) |
| MX (1) | MXPA05010977A (es) |
| WO (1) | WO2007043853A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101512386B1 (ko) * | 2008-04-08 | 2015-04-17 | 제이더블유중외제약 주식회사 | 미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법 |
| KR101189639B1 (ko) * | 2008-12-15 | 2012-10-12 | 씨제이제일제당 (주) | 메트포르민 및 α-글리코시다제 억제제를 포함하는 경구 제제 및 그 제조방법 |
| EP2228066A1 (en) * | 2009-03-03 | 2010-09-15 | LEK Pharmaceuticals d.d. | Pharmaceutical compositions of sulphonylurea-based active pharmaceutical ingredient with excellent dissolution properties |
| WO2011128782A2 (en) * | 2010-04-13 | 2011-10-20 | Jorge Luis Rosado | Compositions and methods for treating type ii diabetes and related disorders |
| US9241952B2 (en) | 2010-05-24 | 2016-01-26 | Ozstar Therapeutics Pty Ltd | Method of treating type II diabetes, hyperglycemia or hypoglycemia by administering a synergistic combination of a sulphonylurea and inulin |
| EP2438911A1 (en) * | 2010-10-08 | 2012-04-11 | LEK Pharmaceuticals d.d. | Pharmaceuticals compositions comprising sulphonylurea-class insulin secretagogue and polyethylene glycol castor oil |
| BR112015011310A2 (pt) * | 2013-05-17 | 2017-07-11 | Athena Drug Delivery Solutions Pvt Ltd | composição de voglibose de desintegração oral e processo para preparar a mesma |
| KR101591357B1 (ko) | 2015-03-24 | 2016-02-04 | 제이더블유중외제약 주식회사 | 미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법 |
| AU2017239641A1 (en) * | 2016-03-30 | 2018-10-18 | Amicus Therapeutics, Inc. | Formulations comprising recombinant acid alpha-glucosidase |
| CN120733024A (zh) * | 2025-08-15 | 2025-10-03 | 可蓝赛生物医药(上海)有限公司 | 一种缓释型佐剂及其制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6011049A (en) * | 1997-02-19 | 2000-01-04 | Warner-Lambert Company | Combinations for diabetes |
| GB9715295D0 (en) * | 1997-07-18 | 1997-09-24 | Smithkline Beecham Plc | Novel method of treatment |
| CZ20011629A3 (cs) * | 1998-11-12 | 2001-12-12 | Smithkline Beecham Plc | Farmaceutický prostředek pro upravené uvolňování senzitizéru inzulínu a jiných antidiabetických přípravků |
-
2005
- 2005-10-12 MX MXPA05010977A patent/MXPA05010977A/es unknown
-
2006
- 2006-06-23 BR BRPI0617409-4A patent/BRPI0617409A2/pt not_active Application Discontinuation
- 2006-06-23 WO PCT/MX2006/000058 patent/WO2007043853A1/es not_active Ceased
- 2006-06-23 EP EP06769370A patent/EP1935424A1/en not_active Withdrawn
-
2008
- 2008-04-07 EC EC2008008353A patent/ECSP088353A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1935424A1 (en) | 2008-06-25 |
| MXPA05010977A (es) | 2007-04-11 |
| WO2007043853A1 (es) | 2007-04-19 |
| BRPI0617409A2 (pt) | 2011-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP088353A (es) | Composiciones farmacéuticas que comprenden sustancias antidiabéticas combinadas para su uso en diabetes mellitus | |
| CL2012001337A1 (es) | Uso de una combinacion farmacéutica que comprende un inhibidor de dpp-4 y opcionalmente un segundo y/o un tercer agente diabético seleccionado entre biguanidas, tiazolidindionas, sulfonilureas, glinidas, inhibidores de alfa-glucosidasa, glp-1 e insulina, diferentes entre ellos, para el tratamiento de diabetes mellitus de tipo 2. | |
| ECSP21080740A (es) | Inhibidores del inflamasoma nlrp3 | |
| UY39786A (es) | Derivados de Triazolopirimidina y su uso en el Tratamiento de Enfermedades | |
| SV2004001415A (es) | Composiciones farmaceuticas para el tratamiento de la diabetes mellitus de tipo ii | |
| AR075421A1 (es) | Composicion farmaceutica, metodos de tratamiento y sus usos | |
| AR077464A1 (es) | Terapia de combinacion para el tratamiento de la diabetes | |
| PE20191615A1 (es) | Compuestos quimicos como inhibidores de la actividad de la interleuquina-1 | |
| WO2008131149A3 (en) | Crystal forms of saxagliptin and processes for preparing same | |
| PE20142316A1 (es) | DERIVADOS DE SULFONAMIDA COMO AGENTES INDUCTORES DE APOPTOSIS CON SELECTIVIDAD POR Bcl-2 PARA EL TRATAMIENTO DE CANCER Y ENFERMEDADES INMUNES | |
| HRP20191614T1 (hr) | Spojevi koji su suagonisti gip i glp-1 | |
| AR084698A1 (es) | Composiciones de liberacion controlada con reducido efecto de alimentos, reducida interaccion entre farmaco y los alimentos | |
| AR110434A2 (es) | Compuestos de naftalenisoxazolina para el control de plagas de invertebrados | |
| CO6251277A2 (es) | Inhibidor de la dpp-iv combinado con mas de un agente antidiabetico, comprimidos que comprenden tales formulaciones, su uso y procedimientos para su preparación. | |
| JP2018507889A5 (es) | ||
| CL2008003153A1 (es) | Compuestos espiro condensados, agonistas de gpr40: composicion farmaceutica que comprende a uno de los compuestos; y el uso de los compuestos en la preparacion de medicamentos para el tratamiento de la diabetes, hiperglicemia, alteracion de tolerancia a la glucosa en ayuna, entre otras. | |
| UY29827A1 (es) | 2-amina-pirimidina-4-(2-metil-1-(tetrahidro-2h-piran-4-il)-1-imidazol-5-y1) sustituidas y sus derivados, composiciones farmacéuticas que las contienen, procesos para su preparación y aplicaciones | |
| UY29791A1 (es) | Sales novedosas de lisina de derivados de acido 4-( (fenoxialquil)tio)-fenoxiacetico | |
| AR063925A1 (es) | Antibacteriales 5-hidroximetil -oxazolidin-2-ona composicion farmaceutica que los comprende y su uso para tratar o prevenir infecciones bacterianas | |
| UY31917A (es) | Compuestos de pirido-pirimidina inhibidores de mtor, composiciones farmaceuticas que los comprenden, procesos para su preparación y su uso como medicamento. | |
| JP2017515908A5 (es) | ||
| PE20061389A1 (es) | Formulacion farmaceutica que contiene biguanida y un derivado de tiazolidinadiona | |
| AR057162A1 (es) | Compuestos de benzamida como inhibidores de la enzima histona desacetilasa (hdac) | |
| AR119143A1 (es) | Compuesto de 1h-pirrolo[3,2-b]piridin-5-ilo, composición farmacéutica que lo comprende y su uso para fabricar un medicamento | |
| RU2012147449A (ru) | Способы использования диацереина в дополнительном лечении диабета |